| Title: |
Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. |
| Authors: |
Yousef, Mahmoud, Hurd, Mark W, Yousef, Abdelrahman, Ludmir, Ethan B, Pillai, Ashwathy B, Peterson, Jennifer, Koay, Eugene J, Albarouki, Sali, Tzeng, Ching-Wei, Snyder, Rebecca, Katz, Matthew H G, Wang, Huamin, Overman, Michael J, Maitra, Anirban, Pant, Shubham, Smaglo, Brandon G, Wolff, Robert A, Yao, James, Shen, John P, Zhao, Dan |
| Source: |
Oncologist; Jan2025, Vol. 30 Issue 1, p1-12, 12p |
| Subject Terms: |
ADENOCARCINOMA, MENINGES, GENOMICS, RESEARCH funding, SYMPTOMS, CANCER patients, RETROSPECTIVE studies, DESCRIPTIVE statistics, PANCREATIC tumors, METASTASIS, DUCTAL carcinoma, MEDICAL records, ACQUISITION of data, GENETIC mutation, BRAIN tumors, MOLECULAR pathology, DISEASE complications |
| Abstract: |
Background The prognosis for patients with pancreatic ductal adenocarcinoma (PDAC) is poor. Secondary brain metastasis (Br-M) occurs in less than 1% of patients. Clinical characteristics and molecular alterations have not been characterized in this rare patients' subset. Materials and methods The Foundry software platform was used to retrospectively query electronic health records for patients with Br-M secondary to PDAC from 2005 to 2023; clinical, molecular, and overall survival (OS) data were analyzed. Results Br-M was diagnosed in 44 patients with PDAC. Median follow-up was 78 months; median OS from initial PDAC diagnosis was 47 months. Median duration from PDAC diagnosis to Br-M detection was 24 months; median OS from Br-M diagnosis was 3 months. At Br-M diagnosis, 82% (n = 36) of patients had elevated CA19-9. Lung was the most common preexisting metastatic location (71%) with Br-M, followed by liver (66%). Br-M were most frequently observed in the frontal lobe (34%, n = 15), cerebellar region (23%, n = 10), and leptomeninges (18%, n = 8). KRAS mutations were detected in 94.1% (n = 16) of patients who had molecular data available (n = 17) with KRASG12V being the most frequent subtype 47% (n = 8); KRASG12D in 29% (n = 5); KRASG12R in 18% (n = 3). Patients who underwent Br-M surgical resection (n = 5) had median OS of 8.6 months, while median OS following stereotactic radiosurgery only (n = 11) or whole-brain radiation only (n = 20) was 3.3 and 2.8 months, respectively. Conclusion Br-M is a late PDAC complication, resulting in an extremely poor prognosis especially in leptomeningeal disease. KRAS was mutated in 94.1% of the patients and the KRASG12V subtype was prevalent. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
